Introduction

Company name: Boehringer Ingelheim Limited

Address: Ellesfield Avenue

Bracknell

Berkshire RG12 8YS

Telephone: Sales & Marketing Enquiries 01344 746959

Telephone: Technical Enquiries 01344 746957

Fax: 01344 741349

Presentation

Solution for injection. Each ml contains 3 mg bromhexine hydrochloride as active ingredient plus 0.7 mg methyl parahydroxybenzoate as preservatives.

Uses

As an aid to the treatment of respiratory disease in cattle and pigs, where mucus is a complicating factor.

Dosage and administration

For intramuscular injection only.

Cattle - 17 ml per 100 kg bodyweight, once daily for 5 days (equivalent to 0.5 mg bromhexine hydrochloride/kg bodyweight).

Pigs - 7 - 17 ml per 100 kg bodyweight, once daily for 5 days (equivalent to 0.2 - 0.5 mg bromhexine hydrochloride/kg bodyweight)

Contra-indications, warnings, etc

Not for use in cows producing milk for human consumption.

Withdrawal periods

Cattle - 28 days

Pigs - 28 days

For animal treatment only.

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority. Care should be taken to avoid accidental self-injection.

Pharmaceutical precautions

Do not refrigerate or freeze.

Following withdrawal of the first dose, use the product within 28 days. Do not dilute or mix with any other components. Discard any unused material.

Should any growth or discolouration occur, the product should be discarded. Avoid the introduction of contamination during use.

Keep the container in the outer carton.

Keep out of the reach and sight of children.

Legal category

POM-V

Packaging Quantities

100 ml multidose amber glass injection bottles with grey rubber stoppers.

Further information

May be used in conjunction with antibiotics and/or sulphonamides. Bisolvon has been shown to increase mucocillary clearance in calves suffering from respiratory disease.

When Bisolvon is administered simultaneously with oxytetracycline in cattle and pigs, the levels of the antibiotic in the bronchial mucus are considerably increased (by more than 40%). The clinical significance of this action is uncertain.

Marketing authorisation number

Vm 00015/4071.